Dr. Engelking is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-648-8088Fax+1 214-648-8804
Summary
- Luke Engelking, MD, is a gastroenterology specialist based in Dallas, TX. He completed his residency in Internal Medicine at Massachusetts General Hospital, and his gastroenterology fellowship at the University of Texas Southwestern Medical Center. He is currently an Associate Professor at UT Southwestern Medical Center, with expertise in general gastroenterology and hereditary intestinal cancer syndromes and is a certified genetic cancer risk assessment specialist. Dr. Engelking serves as the Associate Dean for Medical Student Research and Scholarly Activity. He has multiple notable publications in esteemed journals and has contributed to clinical trials. He has also received several awards for his research achievements, including the Research Scholar in Liver Disease Award from Gilead Sciences, and the Distinguished Researcher Award from UT Southwestern's President's Research Council.
Education & Training
- University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 2010 - 2014
- Massachusetts General HospitalResidency, Internal Medicine, 2007 - 2010
- University of Texas Southwestern Medical SchoolClass of 2007
Certifications & Licensure
- TX State Medical License 2010 - 2026
- MA State Medical License 2009 - 2012
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Research Scholar in Liver Disease Award Gilead Sciences, Inc., 2015
- Disease-Oriented Clinical Scholar UT Southwestern, 2014
- Distinguished Researcher Award, President's Research Council UT Southwestern, 2014
Clinical Trials
- Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese Start of enrollment: 2012 Dec 01
- Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps Start of enrollment: 2021 Oct 06
Publications & Presentations
PubMed
- 49 citationsBlockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytesLuke J. Engelking, Matthew R. McFarlane, Christina Li, Guosheng Liang
Journal of Lipid Research. 2012-07-01 - 29 citationsScap is required for sterol synthesis and crypt growth in intestinal mucosa.Matthew R. McFarlane, Mary Jo Cantoria, Albert G. Linden, Brandon A. January, Guosheng Liang
Journal of Lipid Research. 2015-08-01 - 32 citationsInsig proteins mediate feedback inhibition of cholesterol synthesis in the intestine.Matthew R. McFarlane, Guosheng Liang, Luke J. Engelking
The Journal of Biological Chemistry. 2014-01-24
Press Mentions
- Engelking seeks to balance research and medicineJanuary 19th, 2023
- American Gastroenterological Association selects 18 future leaders March 23rd, 2022
- Journal of Lipid Research Names New Junior Associate EditorsMarch 31st, 2021
Grant Support
- SREBP-Mediated Regulation of Intestinal Epithelial HomeostasisNIDDK2019–2024
- SREBP-2- Dependent Oncometabolites and Intestinal TumorigenesisCancer Prevention & Research Institute of Texas2020–2023
- SREBP-Mediated Lipid Regulation in the IntestineNIDDK2014–2019
Committees
- Member, American Gastroenterogical Association - Publications Committee 2024 - Present
Professional Memberships
- Member
- Member
- American Society for Biochemistry and Molecular BiologyMember
- Collaborative Group of the Americas on Inherited Gastrointestinal CancerMember
External Links
- UTSW Faculty Pagehttp://profiles.utsouthwestern.edu/profile/35166/luke-engelking.html
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: